- Therapeutic Category : Antidepressant
- CAS Number : 508233-74-7
- Molecular Formula : C18H22N2S
- Molecular Weight : 298.4 g/mol
- Mesh Size : As per Customer Requirement
- Form : Capsule, Tablet
- Metrochem Development Status : Pipeline
Mechanism of Action:
Vortioxetine’s mechanism of action is not fully understood. Vortioxetine binds with high affinity to the serotonin transporter (Ki = 1.6 nM) and its antidepressant actions are believed to be secondary to enhancing serotonin in the central nervous system through inhibition of reuptake. Vortioxetine also displays binding affinities to other serotonin (5-HT) receptors, including 5-HT3, 5-HT1A, and 5-HT7, with Ki values of 3.7 nM, 15 nM, and 19 nM, respectively. There is moderate affinity toward serotonin receptors 5-HT1D and 5-HT1B, with Ki values of 54 nM and 33 nM, respectively. Vortioxetine’s binding affinity is dose-proportional: Raising the dose will cause more binding to the receptors of interest at an increase of 15% for every 5 mg up to the maximum dosage. Based on the receptor binding affinities, vortioxetine displays reuptake blockade of the serotonin transporter, agonist activity at the 5-HT1A receptor, partial agonist activity at the 5-HT1B receptor, and antagonism at the 5-HT1D, 5-HT7, and 5-HT3 receptors. It has not been determined whether the antidepressant effects of vortioxetine are related to its binding at various 5-HT receptors.
Vortioxetine is approved for MDD in adults with a starting dose of 10 mg a day and can be increased to 20 mg a day. Providers may consider 5 mg a day for patients who cannot tolerate higher doses. Vortioxetine can be discontinued abruptly, but a decrease to 10 mg a day is recommended for patients who are on 15 mg a day or more for one week before complete discontinuation.10 Vortioxetine is in pregnancy category C. There is no data on its effects with breastfeeding.
Metrochem API Expertise:
Metrochem API Pvt Ltd is a leading manufacturer and supplier of Active Pharmaceutical Ingredients (APIs) through our manufacturing sites in Hyderabad and Vizag. Our API facilities have been inspected and approved by several global regulatory bodies including the US FDA, Japan PMDA, KFDA, and meet the cGMP compliance standards. Adapting quickly to the ever-evolving demands, we have emerged as one of the fastest growing organization in the pharmaceutical industry across the India. To cater our customer high volume requirements, we have dedicated each of our 6 manufacturing facilities to our 3 core product groups – APIs, Pelletization & Intermediates – reinforced by a well-equipped, centralized Research & Development laboratory.
We have been successfully supplying APIs all over the globe for more than 15 years. Total reactor volume exceeds 1200 KL which includes pilot and multi-purpose units. We are capable of executing extensive API requirements for our customers. Metrochem API Pvt Ltd has an experienced team of highly skilled chemists, experienced regulatory professionals and supply chain experts, who are ready to handle your API manufacturing requirements with expert care. We also offer Contract Manufacturing, Contract Research, and Custom Synthesis services. We have a stand-alone R&D center located in Hyderabad with State-of-the-art analytical facilities and over 90 scientists. We have extensively worked on and delivered new products across a wide variety of therapeutic segments and as a company, we have built strong expertise in new product development.
Disclaimer : Metrochem API Pvt Ltd respects the intellectual property rights of others. Some of the Active Pharmaceuticals Ingredients (APIs) listed in the Metrochem’s product list or brochure or in the product list uploaded in Metrochem’s website may be protected by a valid patent in India or in any other countries concerned. However, mentioning of the name of such product(s) in the product brochure or the product list shall not be construed as infringement in any manner whatsoever. Without prejudice to the foregoing, Metrochem’s supply of API being protected by a valid product patent, if any, is intended solely for uses reasonably relating to the development and submission of information required under any law for the time being inforce, in India, or in a country other than India that regulates the manufacture, use, sale or import of the said product, strictly under the conditions as set forth in Section 107A of the Indian patents Act, 1970, as amended in 2005, or an equivalent provision (Bolar exemption) thereof in a country other than India. The disclaimer is applicable till the expiration of the corresponding product patent(s), if any, in the respective. countries concerned. None of the products will be supplied to the countries wherein this could be in conflict with existing laws. However, the final responsibility lies exclusively with the buyer/ultimate customer.